Guardant Health, Inc. (GH) is a publicly traded company in the Healthcare sector, operating within the Medical - Diagnostics & Research industry. The company is headquartered in Palo Alto, CA, United States. The current CEO is Helmy Eltoukhy.
GH has IPO date of 2018-10-04, 1,999 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $11.33B.
Guardant Health, Inc. is a precision oncology company that develops and provides innovative blood-based liquid biopsy tests and analytics for cancer detection and treatment. The company offers a portfolio of products including Guardant360 and its variants for advanced-stage cancer patients, GuardantINFORM for clinical genomic research, and LUNAR-2 for early colorectal cancer detection, as well as GuardantConnect, a software platform connecting patients with relevant clinical trials. Additionally, Guardant Health provides development services to biopharmaceutical companies and medical institutions, including companion diagnostic development, clinical trial support, and testing solutions. Headquartered in Redwood City, California, the company operates globally and serves the oncology market through its comprehensive suite of diagnostic and data analytics offerings.
